Update on Omega-3 Polyunsaturated Fatty Acids on Cardiovascular Health Article

Full Text via DOI: 10.3390/nu14235146 Web of Science: 000896474300001

Cited authors

  • Rodriguez D, Lavie CJ, Elagizi A, Milani RV


  • Twenty percent of deaths in the United States are secondary to cardiovascular diseases (CVD). In patients with hyperlipidemia and hypertriglyceridemia, studies have shown high atherosclerotic CVD (ASCVD) event rates despite the use of statins. Given the association of high triglyceride (TG) levels with elevated cholesterol and low levels of high-density lipoprotein cholesterol, the American Heart Association (AHA)/American College of Cardiology (ACC) cholesterol guidelines recommend using elevated TGs as a "risk-enhancing factor" for ASCVD and using omega 3 fatty acids (omega 3FAs) for patients with persistently elevated severe hypertriglyceridemia. omega 3FA, or fish oils (FOs), have been shown to reduce very high TG levels, hospitalizations, and CVD mortality in randomized controlled trials (RCTs). We have published the largest meta-analysis to date demonstrating significant effects on several CVD outcomes, especially fatal myocardial infarctions (MIs) and total MIs. Despite the most intensive research on omega 3FAs on CVD, their benefits have been demonstrated to cluster across multiple systems and pathologies, including autoimmune diseases, infectious diseases, chronic kidney disease, central nervous system diseases, and, most recently, the COVID-19 pandemic. A review and summary of the controversies surrounding omega 3FAs, some of the latest evidence-based findings, and the current and most updated recommendations on omega 3FAs are presented in this paper.

Publication date

  • 2022

Number of pages

  • 15


  • 14


  • 23